Evidence map›Paper›PMID 24798478›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2014

Single compartment drug delivery.

Michael J Cima, Heejin Lee, Karen Daniel, Laura M Tanenbaum, Aikaterini Mantzavinou, Kevin C Spencer, Qunya Ong, Jay C Sy, John Santini, Carl M Schoellhammer and 2 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Advances in Biomaterials for Drug Delivery.Advanced materials (Deerfield Beach, Fla.) · 2018
    Review
  11. Principles of pharmacology in the eye.British journal of pharmacology · 2017
    Review
  12. Review
  13. Article
  14. Novel targeted bladder drug-delivery systems: a review.Research and reports in urology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael J CimaThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Materials Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: mjcima@mit.edu.
Heejin LeeTARIS Biomedical, Inc., Lexington, MA 02421, USA.
Karen DanielTARIS Biomedical, Inc., Lexington, MA 02421, USA.
Laura M TanenbaumThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Aikaterini MantzavinouThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Kevin C SpencerThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Materials Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Qunya OngThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jay C SyThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
John SantiniOn Demand Therapeutics, Inc., Menlo Park, CA 94025, USA.
Carl M SchoellhammerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Daniel BlankschteinDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Robert S LangerThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Massachusetts Institute of Technology · USHarvard–MIT Division of Health Sciences and Technology · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Angela Nicole Koehler · 1985 to 2026
$93.9M
A New Device for Electrical & Chemical Modulation of Pathological Neural ActivityR01EB016101 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CIMA, MICHAEL J, GRAYBIEL, ANN M · 2013 to 2017
$5.5M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Role of cerebrospinal fluid dynamics in brain drug deliveryK99EB016690 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SY, JAY CHRISTOPHER · 2013 to 2014
$181k
NCI NIH HHS P30 CA014051NIBIB NIH HHS K99 EB016690NIBIB NIH HHS K99EB016690NIBIB NIH HHS R01 EB016101NIBIB NIH HHS R01EB016101NIBIB NIH HHS R37 EB000244NIBIB NIH HHS R37EB000244
6 · The paper itself

Abstract

Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a case. It is, however, common for enzymes or receptors that are integral to disease to be structurally similar or identical to those that play important biological roles in normal tissues of the body. Additionally, systemic administration may not lead to local drug concentrations high enough to yield disease modification because of rapid systemic metabolism or lack of sufficient partitioning into the diseased tissue compartment. This review focuses on drug delivery methods that physically target drugs to individual compartments of the body. Compartments such as the bladder, peritoneum, brain, eye and skin are often sites of disease and can sometimes be viewed as "privileged," since they intrinsically hinder partitioning of systemically administered agents. These compartments have become the focus of a wide array of procedures and devices for direct administration of drugs. We discuss the rationale behind single compartment drug delivery for each of these compartments, and give an overview of examples at different development stages, from the lab bench to phase III clinical trials to clinical practice. We approach single compartment drug delivery from both a translational and a technological perspective.

Indexed as

Delayed-Action PreparationsDrug Delivery SystemsMolecular Targeted TherapyAdministration, IntravesicalCatheterizationDrug DesignHumansDelayed-Action PreparationsControlled release drug deliveryLocal therapyMicrofabricationNoninvasiveSingle compartmentTargeted therapy

Identifiers

PMID24798478
PMCPMC4179298
OpenAlexW2026735896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.